Seaport Therapeutics plans IPO of 11.8 million shares priced at $16-$18 each

2 articles · Updated · MarketWatch · Apr 27

The Boston-based company expects to raise about $183.5 million, or up to $211.4 million if underwriters exercise their option, and will list shares under the symbol SPTX.
Proceeds from the IPO, combined with existing resources, are projected to fund Seaport’s operations into 2029 as it develops medicines for depression, anxiety, and other neuropsychiatric disorders.
After the IPO and overallotment, Seaport Therapeutics would have approximately 52.4 million shares outstanding, giving it a market capitalization exceeding $890 million at the $17 midpoint price.

Is Seaport's IPO a strategic move to attract a Big Pharma acquisition before its pivotal trial results?

With $233M in cash, why is Seaport pursuing a risky IPO now instead of waiting for key data?

How could a government shutdown impact Seaport's IPO timeline and its crucial clinical trials?

Will Seaport's lead drug work for patients who don't respond to today's standard treatments?

How does Seaport's Glyph™ platform promise to overcome the side effects of current antidepressants?